Skip to content

Moisturizing activity of Hydration Serum

A single blind clinical study to evaluate the Moisturizing potential of Hydration Serum - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/01/100030
Enrollment
10
Registered
2026-01-01
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: Hydration serum: Test Product: Hydration Serum Dose: : Apply 0.5gm all over the face Route of Administration: Topical Duration: 28 days Control Intervention1: Not Applicab

Sponsors

Anju LLC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Gender: Female aged Between 40 to 55. 2. Non-pregnant, non-lactating female 3. No acne skin or acne prone skin. 4. Subject willing to give written informed consent 5. Women of child bearing potential must have a negative urine pregnancy test. 6. Free of any systemic and dermatologic disorder, which in the opinion of the investigator, will interface with the study results or increase the risk of AE. The client has specified no subject should have melasma 7. Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study

Exclusion criteria

Exclusion criteria: 1. Subjects who are pregnant, breast feeding, or planning to become pregnant during the study 2. Subjects having Moderate to severe pigmentation, sunburn, scar or any type of skin concern. 3. Volunteers with skin conditions such as eczema, psoriasis, etc 4. Have any evidence of systematic cancer,squamous cell carcinoma, basal cell carcinoma in the last 5 years, or any other confounding skin condition. 5. Have open sore or open lesions in the treatment area 6. Have any condition that, in the opinion of the investigator, would confound the safety and efficacy assessments of the product. 7. Have participated in any interventional clinical trial in the previous 30 days. 8. Have a known sensitivity to any of the constituents of the test product including sensitivities to any of the constituents. 9. Have used, are using, or are planning to use immunosuppressive or immunomodulatory medications (i.e., biologics), including corticosteroids. 10. Have a history of alcohol or illegal drug/ substance abuse or suspected alcohol or illegal drug/substance abuse in the past 2 years.

Design outcomes

Primary

MeasureTime frame
change in skin hydration change in TEWL change in skin firmnessTimepoint: At T0min, 30min, 4hr, 8hr, 24hr, 14 day and 28day

Secondary

MeasureTime frame
Not ApplicableTimepoint: Not Applicable

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026